Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

Stock Information for Pieris Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.